# VYGLXIA (troriluzole) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/troriluzole

> VYGLXIA (troriluzole), sponsored by Biohaven Ltd. (BHVN), received a complete response letter from the FDA; the decision is dated Nov 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, half-year only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | VYGLXIA (troriluzole) |
| Codes | BHV4157 |
| Sponsor | Biohaven Ltd. (BHVN) https://sec-api.dev/companies/bhvn/catalysts |
| Indications | [spinocerebellar ataxia](https://sec-api.dev/indications/spinocerebellar-ataxia), [Obsessive-Compulsive Disorder](https://sec-api.dev/indications/obsessive-compulsive-disorder) |
| Modality |  |
| FDA designations | orphan, priority review |

## Timeline

### Jul 2023: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2025-03-03, last confirmed 2026-03-02.
- SEC Form 10-K (accession 0001935979-26-000020): "In July 2023, the FDA informed us that it would not review the submitted NDA application for troriluzole given that the study's primary endpoint was not met and thus, would not permit a substantive review." https://www.sec.gov/Archives/edgar/data/1935979/000193597926000020/bhvn-20251231.htm
- SEC Form 10-K (accession 0001935979-26-000020): "In July 2023, the FDA informed us that it would not review the recently submitted NDA application for troriluzole given that the study's primary endpoint was not met and thus, would not permit a substantive review." https://www.sec.gov/Archives/edgar/data/1935979/000193597926000020/bhvn-20251231.htm
- SEC Form 10-K (accession 0001935979-25-000015): "In July 2023, the FDA informed us that it would not review the submitted NDA application for troriluzole given that the study's primary endpoint was not met and thus, would not permit a substantive review." https://www.sec.gov/Archives/edgar/data/1935979/000193597925000015/bhvn-20241231.htm
- SEC Form 10-K (accession 0001935979-25-000015): "In July 2023, the FDA informed us that it would not review the recently submitted NDA application for troriluzole given that the study's primary endpoint was not met and thus, would not permit a substantive review." https://www.sec.gov/Archives/edgar/data/1935979/000193597925000015/bhvn-20241231.htm

### Sep 2024: topline data readout

- Status: completed, positive. Date confidence: month.
- First seen 2024-11-12, last confirmed 2026-03-02.
- Press release filed with the SEC (EX-99) (accession 0001935979-24-000086): "•Achieved positive topline results in pivotal study of troriluzole in SCA - In September 2024, the Company announced positive topline results from pivotal Study BHV4157-206-RWE demonstrating the efficacy of troriluzole on the mean change from baseline in the f-SARA after 3 years of treatment." https://www.sec.gov/Archives/edgar/data/1935979/000193597924000086/a2024q3bhvnltdearningsprex.htm
- SEC Form 10-Q (accession 0001935979-25-000054): "In September 2024, we announced positive topline results from pivotal Study BHV4157-206-RWE (NCT06529146) demonstrating the efficacy of troriluzole on the mean change from baseline in the f-SARA after 3 years of treatment." https://www.sec.gov/Archives/edgar/data/1935979/000193597925000054/bhvn-20250331.htm
- SEC Form 10-Q (accession 0001935979-24-000085): "In September 2024, we announced positive topline results from pivotal Study BHV4157-206-RWE (NCT06529146) demonstrating the efficacy of troriluzole on the mean change from baseline in the f-SARA after 3 years of treatment." https://www.sec.gov/Archives/edgar/data/1935979/000193597924000085/bhvn-20240930.htm
- SEC Form 10-K (accession 0001935979-26-000020): "In September 2024, we announced positive topline results from pivotal Study BHV4157-206-RWE (NCT06529146) demonstrating the efficacy of troriluzole on the mean change from baseline in the f-SARA after 3 years of treatment." https://www.sec.gov/Archives/edgar/data/1935979/000193597926000020/bhvn-20251231.htm
- SEC Form 10-K (accession 0001935979-26-000020): "Furthermore, in September 2024, we announced positive topline results from pivotal Study BHV4157-206-RWE (NCT06529146) demonstrating the efficacy of troriluzole on the mean change from baseline in the f-SARA after 3 years of treatment." https://www.sec.gov/Archives/edgar/data/1935979/000193597926000020/bhvn-20251231.htm
- SEC Form 10-Q (accession 0001935979-25-000068): "In September 2024, we announced positive topline results from pivotal Study BHV4157-206-RWE (NCT06529146) demonstrating the efficacy of troriluzole on the mean change from baseline in the f-SARA after 3 years of treatment." https://www.sec.gov/Archives/edgar/data/1935979/000193597925000068/bhvn-20250630.htm
- SEC Form 10-K (accession 0001935979-25-000015): "In September 2024, we announced positive topline results from pivotal Study BHV4157-206-RWE (NCT06529146) demonstrating the efficacy of troriluzole on the mean change from baseline in the f-SARA after 3 years of treatment." https://www.sec.gov/Archives/edgar/data/1935979/000193597925000015/bhvn-20241231.htm

### Q4 2024: interim data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2024-11-12, last confirmed 2024-11-12.
- Press release filed with the SEC (EX-99) (accession 0001935979-24-000086): "•Two Phase 3 trials with troriluzole in OCD; expect to conduct interim analysis of the second Phase 3 OCD trial in 4Q 2024 and report topline data from first Phase 3 OCD trial in 1H 2025" https://www.sec.gov/Archives/edgar/data/1935979/000193597924000086/a2024q3bhvnltdearningsprex.htm

### Q4 2024: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2024-11-12, last confirmed 2024-11-12.
- Press release filed with the SEC (EX-99) (accession 0001935979-24-000086): "•Taldefgrobep alfa, a myostatin-inhibitor, Phase 3 topline data in spinal muscular atrophy (SMA) in 4Q 2024 and Phase 2 trial protocol in obesity expected in 4Q 2024" https://www.sec.gov/Archives/edgar/data/1935979/000193597924000086/a2024q3bhvnltdearningsprex.htm
- Press release filed with the SEC (EX-99) (accession 0001935979-24-000086): "•NDA submission to FDA on track for 4Q 2024, following release of pivotal topline results in SCA in September 2024" https://www.sec.gov/Archives/edgar/data/1935979/000193597924000086/a2024q3bhvnltdearningsprex.htm
- SEC Form 10-Q (accession 0001935979-24-000085): "There is a similarly designed pre-planned IA for the second Phase 3 study in OCD, with topline results from this IA anticipated in the fourth quarter of 2024." https://www.sec.gov/Archives/edgar/data/1935979/000193597924000085/bhvn-20240930.htm
- SEC Form 10-Q (accession 0001935979-24-000085): "We expect to report topline data from our Phase 3 study in the fourth quarter of 2024." https://www.sec.gov/Archives/edgar/data/1935979/000193597924000085/bhvn-20240930.htm

### 1H 2025: topline data readout

- Status: scheduled. Date confidence: half.
- First seen 2025-05-12, last confirmed 2025-05-12.
- Press release filed with the SEC (EX-99) (accession 0001935979-25-000053): "We also look forward to delivering key clinical readouts, including pivotal topline data with troriluzole in obsessive compulsive disorder in 1H 2025 and with our selective Kv7 activator BHV-7000 in major depressive disorder ("MDD") in 2H 2025." https://www.sec.gov/Archives/edgar/data/1935979/000193597925000053/a2025q1bhvnltdearningsprex.htm

### Feb 2025: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2025-03-03, last confirmed 2026-03-02.
- SEC Form 10-K (accession 0001935979-26-000020): "In February 2025, the FDA accepted for review our NDA for troriluzole for the treatment of adult patients with SCA and granted priority review." https://www.sec.gov/Archives/edgar/data/1935979/000193597926000020/bhvn-20251231.htm
- SEC Form 10-Q (accession 0001935979-25-000068): "In February 2025, the FDA accepted for review our NDA for troriluzole for the treatment of adult patients with SCA and granted priority review." https://www.sec.gov/Archives/edgar/data/1935979/000193597925000068/bhvn-20250630.htm
- SEC Form 10-K (accession 0001935979-25-000015): "In February 2025, the FDA accepted for review our NDA for troriluzole for the treatment of adult patients with SCA and granted priority review." https://www.sec.gov/Archives/edgar/data/1935979/000193597925000015/bhvn-20241231.htm

### May 14, 2025: PDUFA date

- Status: scheduled. Date confidence: exact. Indication: spinocerebellar ataxia.
- First seen 2025-05-15, last confirmed 2025-08-22.
- SEC Form 10-Q (accession 0001935979-25-000068): "In May 2025, the Division of Neurology 1 within the FDA's Office of Neuroscience informed us that they were extending the Prescription Drug User Free Act ("PDUFA") date for the troriluzole NDA by three months to provide time for a full review of Biohaven's recent submissions related to information requests from the FDA." https://www.sec.gov/Archives/edgar/data/1935979/000193597925000068/bhvn-20250630.htm
- SEC Form 8-K (accession 0001935979-25-000056): "On May 14, 2025, Biohaven Ltd. (the "Company" or "Biohaven") issued a press release announcing that the Division of Neurology 1 (the "Division") within the U.S. Food and Drug Administration's ("FDA") Office of Neuroscience informed the Company that they are extending the Prescription Drug User Fee Act ("PDUFA") date for the troriluzole new drug application (the "NDA") for the treatment of spinocerebellar ataxia by three months to provide time for a full review of Biohaven's recent submissions related to information requests from the FDA." https://www.sec.gov/Archives/edgar/data/1935979/000193597925000056/bhvn-20250514.htm
- SEC Form 8-K (accession 0001935979-25-000056): "Press Release, dated May 14, 2025, "FDA Extends PDUFA Date of Biohaven's Troriluzole NDA for Rare Disease Spinocerebellar Ataxia"" https://www.sec.gov/Archives/edgar/data/1935979/000193597925000056/bhvn-20250514.htm
- Press release filed with the SEC (EX-99) (accession 0001935979-25-000056): "NEW HAVEN, Conn., May 14, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), today announced that the Division of Neurology 1 within FDA's Office of Neuroscience informed the Company that they are extending the PDUFA date for the troriluzole new drug application (NDA) for the treatment of spinocerebellar ataxia (SCA) by three months to provide time for a full review of Biohaven's recent submissions related to information requests from the FDA." https://www.sec.gov/Archives/edgar/data/1935979/000193597925000056/exhibit9912025troriluzolea.htm
- SEC Form 8-K (accession 0001935979-25-000080): "As previously disclosed, in May 2025, the Division of Neurology 1 (the "Division") within the Office of Neuroscience of the Food and Drug Administration (the "FDA") informed the Company that it was extending the Prescription Drug User Free Act ("PDUFA") date for the troriluzole NDA by three months to provide time for a full review of the Company's recent submissions related to information requests from the FDA." https://www.sec.gov/Archives/edgar/data/1935979/000193597925000080/bhvn-20250821.htm

### Q3 2025: PDUFA date

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-03-03, last confirmed 2025-05-12.
- Press release filed with the SEC (EX-99) (accession 0001935979-25-000016): "•Announced acceptance and Priority Review by the United States Food and Drug Administration (FDA) of the new drug application (NDA) for troriluzole in all-genotype spinocerebellar ataxia; expected Prescription Drug User Fee Act (PDUFA) date in 3Q 2025." https://www.sec.gov/Archives/edgar/data/1935979/000193597925000016/a2024q4bhvnltdearningsprex.htm
- Press release filed with the SEC (EX-99) (accession 0001935979-25-000016): "•Following FDA acceptance of the troriluzole all-genotype SCA NDA filing resubmission with Priority Review status and a 3Q 2025 PDUFA date, the Company is preparing for commercial launch in SCA in 2025, pending approval." https://www.sec.gov/Archives/edgar/data/1935979/000193597925000016/a2024q4bhvnltdearningsprex.htm
- Press release filed with the SEC (EX-99) (accession 0001935979-25-000053): "The NDA had previously been accepted and granted priority review by the FDA with a Prescription Drug User Fee Act ("PDUFA") date expected in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1935979/000193597925000053/a2025q1bhvnltdearningsprex.htm
- Press release filed with the SEC (EX-99) (accession 0001935979-25-000053): "•Preparing for commercial launch in all-genotype SCA in 2025, following NDA acceptance with Priority Review and 3Q 2025 PDUFA date." https://www.sec.gov/Archives/edgar/data/1935979/000193597925000053/a2025q1bhvnltdearningsprex.htm
- Press release filed with the SEC (EX-99) (accession 0001935979-25-000016): "•Preparing for commercial launch in all-genotype SCA in 2025, following FDA filing acceptance and 3Q 2025 PDUFA date." https://www.sec.gov/Archives/edgar/data/1935979/000193597925000016/a2024q4bhvnltdearningsprex.htm
- SEC Form 10-Q (accession 0001935979-25-000054): "The most advanced product candidate from our glutamate receptor antagonist platform is troriluzole (previously referred to as trigriluzole and BHV-4157), which is currently in two Phase 3 trials in OCD and, for which our New Drug Application ("NDA") in Spinocerebellar Ataxia ("SCA") has been accepted with priority review by the United States Food and Drug Administration (the "FDA") with a Prescription Drug User Fee Act date expected in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1935979/000193597925000054/bhvn-20250331.htm

### Q4 2025: PDUFA date

- Status: scheduled. Date confidence: quarter.
- First seen 2025-06-04, last confirmed 2025-08-11.
- Press release filed with the SEC (EX-99) (accession 0001935979-25-000067): "•VYGLXIA NDA for spinocerebellar ataxia (SCA) PDUFA date 4Q2025, completed clinical trial inspections by FDA without observations or findings, and filing review remains ongoing" https://www.sec.gov/Archives/edgar/data/1935979/000193597925000067/a2025q2bhvnearningsprex991.htm
- Press release filed with the SEC (EX-99) (accession 0001935979-25-000067): "•Priority Review of SCA NDA ongoing, with PDUFA expected in 4Q 2025." https://www.sec.gov/Archives/edgar/data/1935979/000193597925000067/a2025q2bhvnearningsprex991.htm
- Press release filed with the SEC (EX-99) (accession 0001935979-25-000058): "PDUFA date 2H 2025 Efficacy and Safety Demonstrated Over 8 Years" https://www.sec.gov/Archives/edgar/data/1935979/000193597925000058/biohaveninvestorpresenta.htm

### October 27, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Obsessive-Compulsive Disorder.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04641143 (Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-27 (ACTUAL); Lead Sponsor Biohaven Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT04641143

### Nov 2025: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: month.
- First seen 2026-03-02, last confirmed 2026-03-02.
- SEC Form 10-K (accession 0001935979-26-000020): "In November 2025, we received a Complete Response Letter ("CRL") for the NDA seeking approval of troriluzole for SCA." https://www.sec.gov/Archives/edgar/data/1935979/000193597926000020/bhvn-20251231.htm

### October 22, 2026: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Indication: spinocerebellar ataxia.
- First seen 2026-10-29, last confirmed 2026-10-29.
- SEC Form 10-Q (accession 0001935979-26-000092): "On October 22, 2026, we announced that the FDA has accepted for review our new drug application ("NDA") resubmission for Vyglxia (troriluzole) for the treatment of spinocerebellar ataxia ("SCA")." https://www.sec.gov/Archives/edgar/data/1935979/000193597926000092/bhvn-20260930.htm

Calendar months: [May 2025](https://sec-api.dev/fda-calendar/2025-05)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/troriluzole.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "VYGLXIA (troriluzole) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/troriluzole

```bibtex
@misc{secapidev_pdufa_troriluzole_20261116,
  title        = {VYGLXIA (troriluzole) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/troriluzole}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_troriluzole_20261116","title":"VYGLXIA (troriluzole) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/troriluzole","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
